DHEA Research: Steroidogenesis, DHEAS and Regulatory Status

DHEA turns up in research catalogues next to peptides, and it is not one. Dehydroepiandrosterone is a C19 steroid built on a fused four-ring carbon skeleton, with no amide bonds and no sequence to report. The distinction is not pedantry. It changes which enzymes act on the molecule, how identity and purity are demonstrated on a certificate, and which regulatory frameworks apply. What follows covers what DHEA research actually supports: how the molecule is assembled in the adrenal cortex, why its sulfated form behaves as a separate entity rather than a storage tank, what the receptor work published since 2022 shows, and why one molecule currently holds three different regulatory statuses at the same time.

What the Evidence Establishes

DHEA is the steroid the human adrenal cortex produces in the greatest quantity, and its sulfate ester DHEAS is the most abundant steroid in human circulation. Both originate principally in the zona reticularis. The biosynthetic route from cholesterol through pregnenolone and 17-hydroxypregnenolone to DHEA is settled biochemistry, as is the enzymology: CYP11A1 performs the first and rate-limiting step, CYP17A1 performs the next two, and SULT2A1 attaches the sulfate.

What DHEA does is a different question, and it separates into three layers that are routinely collapsed into one. Most of the androgenic and estrogenic activity attributed to DHEA is not DHEA's own — it belongs to the downstream steroids that individual tissues make from it. A direct, non-classical mechanism has emerged since 2022, with DHEA and DHEAS characterised as agonists of the adhesion receptor ADGRG2. And the human outcome literature for systemic DHEA administration in healthy older adults is, for the endpoints most often claimed, negative. Pathway, mechanism, and outcome are three separate evidence bases. Keeping them apart is most of what this article is for.

Molecular Identity

The name prasterone carries more weight than it appears to. It is the non-proprietary name for exactly this molecule, and it is the string used both on the FDA-approved product label and on the World Anti-Doping Agency Prohibited List. Searching regulatory databases for "DHEA" and finding nothing means searching the wrong term.

Structurally, DHEA carries a hydroxyl group at C3 in the beta configuration, a double bond between C5 and C6, and a ketone at C17. The double bond and the ketone are not conjugated to one another, and that has a direct analytical consequence. Δ4-3-ketosteroids such as testosterone absorb ultraviolet light strongly near 240 nm because their alkene and ketone sit adjacent. DHEA has no equivalent chromophore. Ultraviolet detection has to run at low wavelength, where selectivity degrades and many co-eluting species are effectively invisible, which is why published steroid assays generally rely on mass spectrometry or derivatise the molecule before analysis.

How DHEA Is Made

Steroidogenesis is a linear pathway with two branch points, and DHEA sits at the second one.

Two features of this sequence are worth pulling out. First, CYP17A1 is one protein performing two chemically distinct reactions, and the ratio between them is not fixed — it is modulated by cytochrome b5, which favours the lyase activity that produces DHEA. The adrenal's output of DHEA versus cortisol precursors is partly a question of how that single enzyme is configured in a given zone. Second, steps 4 and 5 form a cycle, not a one-way arrow, and that cycle is the subject of the next section.

DHEA and DHEAS Are Different Molecules

DHEAS is DHEA bearing a sulfate ester at the 3β position. In mass terms the addition is SO3, roughly 80 Da: the free acid sits near 368.5 g/mol against DHEA's 288.42, and research material is frequently supplied as the sodium salt, which moves the mass basis again. One mass spectrometry run separates the two without ambiguity — which also means a certificate describing "DHEA" should confirm which of the two it characterised.

Published half-life values for both differ by method and population, so no single figure is quoted here. The reproducible point is directional: DHEAS is cleared more slowly and varies less through the day, which is precisely why DHEAS rather than DHEA is the analyte used to index adrenal androgen production.

The sulfation switch

Describing DHEAS as "stored DHEA" names the arrow but misses the control. Sulfation by SULT2A1 requires the universal sulfonate donor PAPS, which is supplied by PAPSS2, and human genetics has already shown what happens when that machinery fails in either direction. Inactivating PAPSS2 variants reduce DHEA sulfation, leave more DHEA available for activation into androgens, and present as androgen excess. Running the other way, X-linked steroid sulfatase deficiency removes the reactivating enzyme; a prepubertal rise in the serum DHEA-to-DHEAS ratio observed in healthy controls is absent in affected individuals, which reads as STS activity being physiologically upregulated before puberty. Sulfation is a regulated switch on androgen availability, and the switch has measurable consequences in people rather than only in cell culture.

Where "inert reservoir" breaks down

DHEAS also appears to do things that are not simply a consequence of being converted back to DHEA. In a reconstituted in vitro system built from purified CYP11A1, adrenodoxin and adrenodoxin reductase, DHEAS increased the conversion of cholesterol by about 26 percent, with difference spectroscopy showing tighter cholesterol binding to CYP11A1 in its presence. That is a sulfated end-product acting on the first and rate-limiting step of the pathway that produced it. Separately, DHEAS was characterised alongside DHEA as an agonist at ADGRG2, and cell-differentiation work has asked whether DHEAS acts directly or only after desulfation.

None of that makes DHEAS a well-characterised signalling molecule; these are in vitro observations in defined systems. It does mean the shorthand is wrong in a way that matters for experimental design. A finding demonstrated for DHEAS is not automatically a DHEA finding, and the reverse holds equally.

Circulating DHEA Is Not Tissue Steroid Exposure

The intracrine model is the reason a serum DHEA value answers fewer questions than it appears to. DHEA delivered to a tissue is acted on by whichever enzymes that tissue expresses. Where HSD3B2 and HSD17B are abundant, the route runs toward testosterone and, with SRD5A, toward dihydrotestosterone. Where CYP19A1 is abundant, the same substrate runs toward estrone and estradiol. Where SULT2A1 dominates, it runs back to DHEAS and out of circulation as an active precursor.

The practical consequence is that two tissues sampled from the same individual, drawing on the same circulating pool, can generate entirely different local steroid environments. Saying that DHEA "converts to testosterone" is true only as a statement about one possible route in one enzymatic context. It is not a description of what a given cell type does.

Receptor Research: ADGRG2 and Steroid-Sensing Adhesion Receptors

The most substantive recent development in DHEA mechanism research is not about steroid receptors at all. Work published in Nature Chemical Biology in 2022 screened 37 steroid hormones against a binding pocket in ADGRG2 (also known as GPR64), an adhesion G protein-coupled receptor previously treated as an orphan. Four activators emerged — androstenedione, DHEA, DHEAS, and 20α-hydroxycholesterol — and DHEA and DHEAS were characterised in detail as the more efficacious pair. Deoxycorticosterone was identified as an endogenous antagonist. Cryo-EM structures of DHEA bound to both the full-length receptor and a truncated construct resolved two distinct binding modes, one higher in the pocket involving a structured water molecule and one deeper in the transmembrane region.

A 2026 review in Pharmacology Research and Perspectives places this in a wider pattern: the DHEA pocket in ADGRG2 partially resembles the cortisol-binding site in the related receptor ADGRG3, sharing three conserved hydrophobic residues, while diverging enough in the extracellular loops to tilt the steroid core. A 2025 paper, again in Nature Chemical Biology, reported a nanobody acting as a positive allosteric modulator that enhanced DHEA-induced ADGRG2 activation and rescued signalling in disease-associated receptor mutants, tested in a mouse model of testicular inflammation.

Three qualifications keep this in proportion. ADGRG2 is characterised principally in the male reproductive tract, where it works with CFTR in fluid reabsorption — the biological context is narrow, not systemic. The evidence is structural, cell-based and murine, not human physiology. And DHEA is not a selective ADGRG2 ligand: androstenedione activates the same receptor, which undercuts any framing of DHEA as uniquely privileged there.

What Human Trials Show

The most informative human dataset for systemic DHEA is a two-year randomised, double-blind, placebo-controlled trial published in the New England Journal of Medicine in 2006, involving 87 elderly men and 57 elderly women selected for low DHEAS. The intervention worked pharmacologically — circulating DHEAS rose substantially against placebo. It did not translate. The investigators found no effect on body composition, physical performance, insulin action or quality of life, and a minimal and inconsistent effect on bone mineral density far smaller than that of established osteoporosis therapies. Their stated conclusion argued against use as an antiaging supplement.

Set against that is the one context where human evidence is positive, and it is instructive precisely because it is local rather than systemic. Prasterone vaginal inserts were approved by the FDA in November 2016 for moderate to severe dyspareunia as a symptom of vulvar and vaginal atrophy due to menopause, supported by two 12-week placebo-controlled trials enrolling 255 and 558 postmenopausal women. That is the intracrine model working as described: the substrate is delivered to a tissue that possesses the enzymes to convert it locally. It says nothing about systemic administration in healthy adults, and it is not a general endorsement of the molecule.

What the Evidence Does Not Establish

• Systemic DHEA administration has not been shown in randomised human trials to improve body composition, physical performance, insulin action or quality of life in healthy older adults.
• An approved local formulation for one menopausal symptom does not establish efficacy for any systemic indication, at any exposure.
• The ADGRG2 structural work establishes that DHEA and DHEAS bind and activate a specific receptor. It does not establish that this pathway contributes meaningfully to human physiology, and it does not establish any clinical effect.
• A decline in DHEAS with age is a well-documented association. No trial has shown that restoring the measurement restores anything the measurement was standing in for.
• Mechanisms demonstrated for DHEAS cannot be attributed to DHEA, and DHEA findings cannot be transferred to DHEAS, because the two differ in transport, clearance and enzyme substrate status.
• A circulating DHEA or DHEAS concentration does not predict local androgen or estrogen exposure in any particular tissue.
• In vitro and mouse findings, including the receptor work discussed above, do not establish human efficacy for anything.

Regulatory Status: One Molecule, Three Answers

DHEA occupies an unusual regulatory position, and the apparent contradictions dissolve once it is clear that status attaches to a product in a context rather than to a molecule in the abstract.

Two implications follow that are easy to miss. Athletes subject to anti-doping rules face prohibition regardless of how the material was obtained, because the list names the substance rather than the product category. And research-use-only labelling is a statement about what the material is sold for; it is not a lighter version of an approval. Helix Bio's research-grade DHEA is supplied for laboratory, analytical and scientific research, and the same research-use-only framework applies to it as to the peptide catalogue, despite DHEA not being a peptide. The medical disclaimer sets out the same position in the site's own terms.

Sourcing and Documentation

For a steroid rather than a peptide, the documentation questions shift. Sequence and net peptide content are not applicable. Identity rests on chromatographic retention matched against a reference standard plus mass spectrometric confirmation, and the chromophore problem described earlier means the detection method deserves scrutiny rather than acceptance. The general certificate of analysis principles still apply — lot-specific documentation, a named method, a stated test date — but the specific checks are different, and a template written for peptides will not ask the right questions of a C19 steroid. DHEA is not the only non-peptide compound that ends up in peptide catalogues; the same category mismatch applies to 5-Amino-1MQ, a quinolinium small molecule.

DHEA is one of the better-characterised molecules in endocrinology at the level of structure and pathway, and one of the less settled at the level of what its administration accomplishes. Those two facts sit together comfortably. The enzymology is not in dispute; the outcomes are. Research that keeps the distinction visible is more useful than research that lets a clean biosynthetic diagram stand in for evidence that has not been generated.